Value of prostate imaging reporting and data system version 2.1 based on magnetic resonance combined with free PSA/total PSA in early diagnosis of prostate cancer
Objective To explore the value of prostate imaging reporting and data system version 2.1(PI-RADS V2.1)based on magnetic reso-nance combined with free prostate specific antigen(PSA)/total PSA in early diagnosis of prostate cancer.Methods A total of 82 patients with early prostate cancer admitted to Nantong Second People's Hospital,Jiangsu Province between June 2018 and June 2022 were screened as canceration group;and 82 patients with benign prostatic hyperplasia admitted at the same time were selected as benign group.Serum PSA test results and magnetic resonance scan results were collected in two groups,and the influencing factors of early prostate cancer were analyzed;the diagnostic efficacy of free PSA/total PSA and PI-RADS V2.1 scores for early prostate cancer were evaluated.Results The total PSA level of canceration group was higher than that of benign group,while the free PSA/total PSA was lower than that in benign group(P＜0.05).The PI-RADS V2.1 score in transition zone of canceration group was higher than that of benign group(P＜0.05).Total PSA,free PSA/total PSA,and PI-RADS V2.1 score in transition zone were influencing factors for early prostate cancer(P＜0.05).The area under the curve of free PSA/total PSA and PI-RADS V2.1 in transition zone in the diagnosis of early prostate cancer was higher than that of each indicator alone.Conclusion Free PSA/total PSA and PI-RADS V2.1 can be used to assist in the diagnosis of prostate cancer,and their diagnostic efficacy is well.
ProstateProstate specific antigenMagnetic resonanceProstate imaging reporting and data system version 2.1Diagnosis
万方数据
维普
